The cumulative review of the elexacaftor–tezacaftor–ivacaftor data, including from clinical trials, post-marketing reports, an ongoing registry-based post authorisation safety study, and peer-reviewed literature, suggests that depression symptoms and depression-related events reported in people with cystic fibrosis treated with elexacaftor–tezacaftor–ivacaftor are gen erally consistent with background epidemiology of these events in the cystic fibrosis population and do not suggest a causal relationship with CFTR modulator treatment. The gene discussed is CFTR; the disease is depressive symptom measurement.